Abstract-The authors evaluated the long-term efficacy and safety of botulinum toxin type A (BTX-A) in poststroke spasticity patients who completed a 12-week placebo-controlled study and received multiple open-label treatments with 200 to 240 U BTX-A for 42 weeks. Significant and sustained improvements were observed for Disability Assessment and Ashworth scores. Adverse events were generally mild. This extension of a double-blind study demonstrates that repeated treatments of BTX-A significantly improve function and tone in spasticity.
Spasticity resulting from stroke is characterized by increased muscle tone, abnormal limb posture, excessive contraction of antagonist muscles, and hyperactive reflexes. 1 Spasticity can cause pain and interfere with activities of daily living. 2 In controlled [3] [4] [5] and open-label 6, 7 studies, botulinum toxin type A (BTX-A) treatment has improved upper limb spasticity and limb functioning. 5, 6 In a 12-week double-blind, placebo-controlled study of poststroke spasticity patients, we reported that a single BTX-A treatment was significantly more effective than placebo in reducing muscle tone and improving function. 5 We present these findings with additional follow-up safety and efficacy data from an open-label study.
Materials and methods.
Design. Data were collected from patients enrolled in two consecutive, multicenter studies: a 12-week double-blind, placebo-controlled, single-treatment trial (Period 1), 5 and a 42-week open-label follow-up study (Period 2) using up to three additional treatments.
BTX-A is a distinct serotype of botulinum toxin with a mechanism and duration of action that differs from other neurotoxin serotypes. Units of biologic activity of BOTOX, which undergoes a specific manufacturing and formulation process, cannot be compared with or converted into units of any other neurotoxin assessed with any other specific assay method.
Population. Inclusion and exclusion criteria were identical for Periods 1 and 2 and can be reviewed in the previous study. 5 Intervention. Most patients received IM injections of 200 to 240 U of BTX-A (BOTOX commercial lot 2024, Allergan, Inc., Irvine, CA) into four required wrist and finger muscles as previously described 5 using EMG guidance or nerve stimulation. Patients were eligible for re-treatment at any subsequent evaluation if Ashworth Scale (ASH) 8, 9 scores were Ն2 points for wrist flexor tone and Ն1 point for finger flexor tone and a minimum of 12 weeks had elapsed since their last treatment. Not all patients would realize minimum reinjection requirements within the same timeframe; therefore, the interval between treatment cycles would vary. The last treatment was to occur at or before week 42. Outcome measures. Efficacy. Functional disability. The 4-point Disability Assessment Scale (DAS; 0, no disability; 1, mild disability; 2, moderate disability; and 3, severe disability) assessed four domains (hygiene, dressing, pain, and limb position). Improvements in DAS scores correlate positively with improvements in ASH scores. 8 Muscle tone. At each visit, the same trained investigator (when possible) assessed wrist, thumb, and finger flexor tone using the 5-point ASH Scale, with 0 indicating normal muscle tone and 4 indicating rigid flexion. 9 Neutralizing antibodies. Neutralizing antibodies were tested using the mouse protection assay (MPA). 10 Safety. Adverse events were recorded throughout the study. Schedule of assessments. Baseline patient DAS and ASH scores were obtained at day 0 of Period 1. Patients were assessed at least every 6 weeks for a maximum of 54 weeks.
Statistical methods. All patients enrolled in the open-label study receiving treatment in either the double-blind or the openlabel study were included in the intent-to-treat (ITT) population from the time BTX-A was first administered.
Baseline frequency distribution scores and summary statistics were calculated for efficacy variables as appropriate. A two-sided 95% CI was calculated based on the t-distribution to estimate the mean change from baseline score at each visit. All safety assessments were summarized according to the number of treatments received during both studies. Doses and injections. Mean dose per treatment was 220 U across all treatment cycles during which patients received an average of 2.8 treatments (see figure 1) . For 61% of patients, there were 12 to 15 weeks between cycles, with the remainder requiring longer dosing intervals but none Ͼ24 weeks.
Disability Assessment Scale. Significant improvements compared with the double-blind baseline scores were observed for each DAS domain 6 weeks after each treatment as determined by CIs ( figure 2) .
Hygiene. The mean baseline score for hygiene was 1.8 (moderate disability). Mean decreases in DAS were sustained across the four cycles (range, 0.7 to 0.9 points). The percentage of patients reporting a 1-, 2-, or 3-point improvement ranged from 50 to 61% during the course of the treatment cycles.
Dressing. The mean baseline score was 2.1, indicating moderate disability. Mean decreases in DAS scores were sustained across the four cycles (range, 0.5 to 0.6 points). The percentage of patients reporting a 1-, 2-, or 3-point improvement ranged from 40 to 45% during the course of the treatment cycles.
Pain. The mean baseline score was~0.74, indicating mild disability. Mean decreases in DAS scores were sustained across the four cycles (range, 0.3 to 0.6 points). The percentage of patients reporting a 1-, 2-, or 3-point improvement ranged from 25 to 33% during the course of the treatment cycles.
Limb position. The mean baseline score was~2.0, indicating moderate disability. Mean decreases in DAS scores were sustained across the four cycles (range, 0.6 to 0.8 points). The percentage of patients reporting a 1-, 2-, or 3-point improvement ranged from 46 to 60% during the course of the treatment cycles.
Ashworth Scale. Significant and sustained improvements from baseline were noted at week 6 of each treatment cycle for wrist, finger, and thumb scores, but the improvements across treatment cycles were not significantly different from each other.
Week 6 mean wrist scores decreased 1.4 to 1.8 points across treatment cycles from a baseline score of 3.1. The percentages of patients who demonstrated a Ն2-point improvement in wrist muscle tone at 6 weeks were 48.2% after the first treatment and 61.5% after the fourth treatment. Week 6 mean finger scores decreased 1.2 to 1.5 points across treatment cycles from a mean baseline score of 3.1 points. Week 6 mean thumb scores decreased 1.1 to 1.9 points across treatment cycles from a mean baseline score of 2.3 points.
Neutralizing antibodies. For the 110 patients who received at least one BTX-A dose in either period, there were 207 post-treatment serum samples of sufficient quantity for neutralizing antibody analysis. One patient, who received four treatments, tested positive after the first injection for neutralizing antibodies. This patient did not respond to BTX-A treatment.
Safety. Mild or moderate adverse events were reported in 56.4% (62/110) of patients during the first cycle, decreasing to 30.8% (8/26) by the fourth. Treatment-related adverse events were reported by 18.2% (20/110) of patients (table) . The most frequently reported treatment-related adverse events were muscle weakness (5.5%, 6/110) and injection-site pain (3.6%, 4/110). One patient discontinued the study for severe muscular weakness and increased in- 5 coordination in the right hand and since recovered. The adverse event profiles were similar whether patients first received treatment in Period 1 or 2, with no clinically relevant differences in the incidence or type of adverse events by treatment cycle or total number of treatments.
Discussion. Repeated BTX-A injections safely and effectively reduced upper limb spasticity after stroke, resulting in significant and sustained improvements in disability and in wrist, thumb, and finger flexor tone. BTX-A treatment-related improvements in function were sustained across the treatment cycles, especially for hygiene and limb position. In addition to muscle tone reduction, improvements in function may be increasingly considered as part of an overall treatment plan for patients with spasticity after a stroke. Treatment-related adverse events were uncommon and generally mild, with no treatmentrelated systemic or CNS side effects. No serious adverse events were related to treatment, and treatment-related events did not increase in frequency or severity as treatment progressed. Patients could have more than one adverse event.
